2w ago · 1 article

Minor

Eli Lilly (LLY) keeps its lead as Novo scrambles in China obesity race

New diabetes data from Novo Nordisk's China pipeline shows it still trailing Eli Lilly (LLY) in the fight for the obesity and diabetes market. Lilly already sells the world's best-selling drug in the category, so a rival racing to catch up in China keeps the momentum on Lilly's side. David J. Taylor holds it long.

Exposure

David J. Taylor

Sources

Lilly vs Novo Nordisk Obesity Drug War: Foundayo Diabetes Data Adds to Novo's China Pipeline Scramble

The whole story · updated 2w ago

Lilly touts Foundayo advantage over Novo's Ozempic pill in diabetes analysis

Novo Nordisk to license GLP-1 drug from China's Hengrui in $2.6 billion deal

Jury tells Eli Lilly (LLY) to pay Nektar $90M over a broken drug deal